CHEMM ChemoMetec

Notification of managers’ transactions

Notification of managers’ transactions

ANNOUNCEMENT NO. 302

2 March 2026

Notification of managers’ transactions

ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.

See the transactions of the Member of ChemoMetec’s Board of Directors Betina Hagerup in the attached PDF document.

For further information, please contact:

Kim Nicolajsen, CFO

Telephone (+45) 48 13 10 20

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to .

Attachment



EN
02/03/2026

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 1 director

A director at ChemoMetec A S bought 71,400 shares at 280.328DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

4h / 39m 4h / 39m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 304                 26. marts 2026 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetninger om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetninger af næstformand for bestyrelsen Martin Glensbjergs transaktioner i vedhæftede pdf-dokumenter. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 4...

7h / 26m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 304 26 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notifications pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Vice Chair of ChemoMetec’s Board of Directors Martin Glensbjerg in the attached PDF documents. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) ...

7h / 26m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Justering af forventningerne til 2025/26

Justering af forventningerne til 2025/26 MEDDELELSE NR. 303 24. marts 2026 Justering af forventningerne til 2025/26 Over den seneste periode har ChemoMetecs væsentligste marked, det nordamerikanske marked for celle- og genterapi, været påvirket af tre forhold, der påvirker salget af vores produkter negativt: I efteråret 2025 var det amerikanske marked og vores kunder påvirket af nedlukningen af statsapparatet, og efterfølgende har der været en fortsat generel tilbageholdenhed hos en række kunder blandt andet som følge af den geopolitiske og makroøkonomiske usikkerhed. Dette har medført ...

March 24, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Adjustment of guidance for 2025/26

Adjustment of guidance for 2025/26 ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been affected by three factors that negatively affect the sales of our products: In the autumn of 2025, the US market and our customers were affected by the lockdown of the government apparatus, and subsequently there has been a continued general restraint among a number of customers, partly as a result of the geopolitical and macroeconomic uncertainty. This has led to p...

March 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch